| Multiple Myeloma studied in …STUDIED_INderived200 of 3,384show all (up to 200) |
|---|
| → studied in | NCT00423644Phase 2 · completed A Phase II Trial of ZIO-101 in Advanced Multiple Myeloma: Protocol SGL2001b · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01559935Phase 2 · completed Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05228470Phase 2 · completed A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. · condition mapped ALIAS · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05354557Phase 2 · active not recruiting Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06055075Phase 1/Phase 2 · terminated A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06179888Phase 2 · suspended Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06876142Phase 1/Phase 2 · suspended Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391657Phase 3 · recruiting A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07409246Phase 1 · recruiting A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01676805recruiting Tissue Collection for Studies of Lymph Cancer · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02473757enrolling by invitation Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02682667recruiting Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03412877Phase 2 · recruiting Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04181827Phase 3 · active not recruiting A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722146Phase 1 · active not recruiting A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04973605Phase 1/Phase 2 · recruiting A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05050097Phase 1 · active not recruiting A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05288062Phase 2 · terminated Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05874193Phase 2 · withdrawn A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06421675Phase 2 · recruiting Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06425991Phase 1 · active not recruiting A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948084Phase 2 · recruiting Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07660939Phase 1 · recruiting GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07740317not yet recruiting Neurocognitive Trajectories After BCMA CAR-T · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01745588Phase 2 · completed Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02538198Phase 2 · active not recruiting Lenalidomide Maintenance in Plasma Cell Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02619682Phase 2 · completed Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03702309recruiting Liquid Biopsy Evaluation and Repository Development at Princess Margaret · condition mapped ALIAS · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04108195Phase 1 · active not recruiting A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04133636Phase 2 · active not recruiting A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04876248Phase 2 · active not recruiting Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04923893Phase 3 · active not recruiting A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05083169Phase 3 · active not recruiting A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05160584recruiting A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05201781Phase 4 · recruiting A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05438043Phase 3 · active not recruiting A Study of Daratumumab · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455320Phase 3 · active not recruiting A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05552222Phase 3 · recruiting A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05572229Phase 2 · active not recruiting Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05623020Phase 3 · recruiting A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06052826Phase 2 · recruiting Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06169215Phase 2 · active not recruiting Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208150Phase 3 · active not recruiting A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06477783recruiting Study on the Clinical Efficacy of Teclistamab and Talquetamab · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06500884Phase 2 · recruiting A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06550895Phase 2 · active not recruiting A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06577025Phase 2 · active not recruiting A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06604715Phase 1 · active not recruiting A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06768489Phase 1 · recruiting A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06910670NA · active not recruiting Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07030517Phase 4 · active not recruiting A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07073547Phase 1 · recruiting A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07149857Phase 2 · recruiting A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07258511Phase 3 · recruiting A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07266441Phase 2 · active not recruiting A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07336472Phase 1/Phase 2 · recruiting A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07518186Phase 3 · recruiting A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07665450Phase 3 · recruiting A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714044recruiting Rutgers University Study of the Genetics of Blood Cancers · condition mapped ALIAS · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07842198Phase 2 · not yet recruiting Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05552976Phase 3 · active not recruiting A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06398457early Phase 1 · recruiting Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07477587Phase 1 · recruiting A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03993912Phase 3 · completed Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05789303Phase 2 · recruiting Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784167recruiting Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07116616Phase 1/Phase 2 · recruiting A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00339963completed Genome Expression in Lymphoma, Leukemia and Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00352924active not recruiting Agriculture Health Study · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02693535Phase 2 · recruiting TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03628612Phase 2 · enrolling by invitation Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05231629Phase 2 · active not recruiting Sequential Therapy in Multiple Myeloma Guided by MRD Assessments · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05376345Phase 1 · completed BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06103838Phase 2 · recruiting 18F-Fluciclovine PET/CT in Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06465316Phase 1 · recruiting Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07095452Phase 2/Phase 3 · recruiting A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07833046not yet recruiting Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03909412Phase 1 · recruiting Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04096066Phase 3 · active not recruiting A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04661137Phase 2 · recruiting A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04920084NA · active not recruiting A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) · condition mapped ONTOLOGY_EXACT · 3,384 trials mapped (972 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04935684Phase 2 · recruiting Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation · condition mapped ALIAS · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06474182NA · recruiting Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06997081Phase 2 · recruiting ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07096778Phase 2 · recruiting Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07802717Phase 1 · recruiting A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07830485Phase 2 · not yet recruiting CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07831122Phase 1 · not yet recruiting Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439253Phase 2 · active not recruiting Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04933539Phase 2 · active not recruiting Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05013190active not recruiting A Study of NINLARO® in Chinese Adults With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07210047Phase 1/Phase 2 · recruiting Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07382739Phase 2 · recruiting A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07809594Phase 1 · active not recruiting CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07828522Phase 2 · not yet recruiting F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03672318Phase 1 · active not recruiting Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04071457Phase 3 · active not recruiting S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04879043Phase 1/Phase 2 · recruiting Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04910568Phase 1 · recruiting A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05827016Phase 3 · active not recruiting A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07585760Phase 2 · recruiting CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07623798Phase 3 · recruiting A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07760454Phase 1/Phase 2 · recruiting A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07823959not yet recruiting CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07825064Phase 2 · recruiting Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00900198recruiting Collection of Tissue Samples for Cancer Research · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01947140Phase 1/Phase 2 · terminated Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03389347NA · completed High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04635189Phase 2 · active not recruiting Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04883242Phase 2 · active not recruiting Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05283993recruiting A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05892393Phase 1 · recruiting Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06832865Phase 2 · recruiting ELISA in Relapsed/Refractory MM · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07181941Phase 1/Phase 2 · recruiting Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07297160Phase 1 · withdrawn CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors · condition mapped ALIAS · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03004287Phase 2 · active not recruiting 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04497961Phase 2 · active not recruiting A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04756401Phase 2 · active not recruiting Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06182774Phase 3 · recruiting Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06215118Phase 1 · active not recruiting A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06303167Phase 2 · active not recruiting Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06308822Phase 2 · active not recruiting Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06615479Phase 3 · recruiting A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06976476Phase 2 · recruiting Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07532473not yet recruiting REal World MAIA UK OutcomEs · condition mapped ALIAS · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07620275Phase 1 · recruiting Safety and Efficacy of KSVCBD Injection in Multiple Myeloma Expressing CD19 and/or BCMA · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01279694Phase 1/Phase 2 · completed Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP) · condition mapped ALIAS · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01309334Phase 3 · completed Imaging Young Myeloma (IMAgerie JEune Myélome) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01936532Phase 2 · completed Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01971658Phase 3 · completed Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04314752recruiting Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04649073Phase 1/Phase 2 · terminated Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06297226Phase 2 · recruiting Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06514508Phase 3 · recruiting Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06827860Phase 2 · recruiting Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06953960Phase 1/Phase 2 · recruiting A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07085728Phase 2 · recruiting Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure · condition mapped ALIAS · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07558915Phase 1 · recruiting A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04579523Phase 1 · withdrawn ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04965155Phase 2 · active not recruiting A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone) · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06049290Phase 1/Phase 2 · recruiting A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06517017Phase 2 · recruiting Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07342114Phase 1 · active not recruiting A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participnats With With Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07455851Phase 1/Phase 2 · recruiting A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07555938Phase 3 · recruiting Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06572605Phase 1/Phase 2 · suspended External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07776964NA · not yet recruiting Monitoring for CardioToxicity Using WeArable deVices While Undergoing cancEr Treatments (MCT-WAVE) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07811986Phase 2 · not yet recruiting HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04124497Phase 2 · active not recruiting A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05001087recruiting A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05320809Phase 1 · completed Study of 3D189 in Patients With Hematologic Malignancies · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05519085Phase 3 · recruiting A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06980480Phase 3 · recruiting A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07746232not yet recruiting Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study" · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439136Phase 2 · active not recruiting Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07624513Phase 3 · not yet recruiting D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06262789NA · recruiting RAT-HEMATO : Return to Work After Malignant Hemopathy · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07637578Phase 2 · recruiting A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05208307Phase 2 · recruiting Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583617Phase 1/Phase 2 · recruiting A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05927571Phase 1 · recruiting A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06232044Phase 1/Phase 2 · suspended Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06822972Phase 2 · recruiting HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07493135early Phase 1 · recruiting A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07601100Phase 1/Phase 2 · not yet recruiting Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05900882Phase 2 · completed SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06183489Phase 2 · active not recruiting Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma · condition mapped ONTOLOGY_EXACT · 3,384 trials mapped (972 active) | — | — | Smoldering Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06988488Phase 1/Phase 2 · recruiting A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07029776Phase 2 · not yet recruiting MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06390852Phase 2 · active not recruiting Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E) · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06523699Phase 1 · active not recruiting Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05272826Phase 2 · recruiting Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05622669completed Understanding Patterns of Fatigue in Health and Disease · condition mapped ALIAS · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06138275Phase 2 · recruiting Elranatamab in R/R Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07479979Phase 1/Phase 2 · recruiting Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00602641Phase 3 · active not recruiting Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01139476completed Specimen Collection for Agricultural Health Study Cohort Pesticide Exposure Study · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05344833Phase 2 · recruiting Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06285318recruiting A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06375044Phase 1 · recruiting Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06934044Phase 1 · active not recruiting A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07075185Phase 1 · recruiting A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07589634Phase 2 · recruiting A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03271632Phase 1/Phase 2 · not yet recruiting Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05836896Phase 1 · recruiting A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06158841Phase 3 · active not recruiting Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06429150Phase 1/Phase 2 · not yet recruiting Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07681596Phase 1/Phase 2 · recruiting A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07789522Phase 2 · not yet recruiting Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00114101Phase 3 · active not recruiting Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06006741Phase 1 · not yet recruiting Universal CAR-T Cells Targeting Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06328699NA · active not recruiting Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06940297Phase 2 · recruiting Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma · condition mapped CURATED_BROADER · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07648459Phase 2 · not yet recruiting CM336-SOC for Dynamically High-Risk Multiple Myeloma Study · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07227311Phase 2 · recruiting A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07783607NA · not yet recruiting MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07785505not yet recruiting Musculoskeletal Ultrasound in Patients With Hematologic Malignancies · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01297764Phase 1/Phase 2 · active not recruiting A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020236Phase 3 · recruiting A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments · condition mapped CURATED_EXACT · 3,384 trials mapped (972 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |